Collaboration Key to Overcoming Obstacles to Drug Development

New AAMC/FDA Report Highlights Partnership Opportunities

link from fda.gov/aamc.org


Washington, D.C., August 15, 2005 - Industry, academic medicine, and government researchers are calling for new and increased collaborations among pharmaceutical companies, academic researchers, and regulatory agencies to strengthen the processes that move scientific breakthroughs to novel diagnostics and therapeutics that benefit the public. A January conference, sponsored by the AAMC (Association of American Medical Colleges) and the U.S. Food and Drug Administration (FDA), and part of the FDA's Critical Path Initiative, was the basis for a new report that describes an array of immediate opportunities for stakeholders to work together toward breakthroughs in the drug development sciences.